📰 Viral Vector Core News
Viral Vector Core News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Viral Vector Core. Real-time updates on events, politics, business and more.
April 3, 2023
Relief Therapeutics Holding SA / Key word(s): Personnel Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board 03-Apr-2023 / 07:00
April 3, 2023
Relief Therapeutics Holding SA / Key word(s): Personnel03-Apr-2023 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific...
April 3, 2023
Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping ...
April 3, 2023
Relief Therapeutics Holding SA / Key word(s): Personnel Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board 03-Apr-2023 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsib...
January 5, 2023
/PRNewswire/ -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today...
October 13, 2022
CANbridge Pharmaceuticals to Participate in Upcoming Investor Conferences - October 13, 2022 - read this article along with other careers information, tips and advice on BioSpace
October 13, 2022
Gene Therapy Data to be Presented at the European Society of Gene and Cell Therapy CANbridge Pharmaceuticals, Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed
May 17, 2022
CANbridge-UMass Chan Medical School Gene Therapy Research Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - read this article along with other careers information, tips and advice on BioSpace
December 21, 2021
The FDA has imposed a clinical hold on a Phase Ib trial assessing Pfizer’s mini-dystrophin gene therapy candidate PF-06939926 in Duchenne muscular dystrophy (DMD), after the company acknowledged the death of a young male participant in the open-label study.
November 3, 2021
/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced...